BioNTech SE (NASDAQ:BNTX) Sees Large Increase in Short Interest

BioNTech SE (NASDAQ:BNTX) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,550,000 shares, an increase of 9.4% from the December 15th total of 2,330,000 shares. Based on an average daily volume of 806,600 shares, the short-interest ratio is presently 3.2 days.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently modified their holdings of the stock. Planning Capital Management Corp boosted its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. Blue Trust Inc. boosted its holdings in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC grew its position in BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after acquiring an additional 111 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in BioNTech during the third quarter worth about $210,000. Finally, Probity Advisors Inc. purchased a new position in shares of BioNTech in the 3rd quarter worth about $216,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. HSBC increased their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their target price for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. Finally, Wells Fargo & Company assumed coverage on BioNTech in a research note on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Trading Down 0.7 %

NASDAQ BNTX traded down $0.83 during mid-day trading on Friday, reaching $111.93. 458,339 shares of the stock were exchanged, compared to its average volume of 565,513. The business’s fifty day simple moving average is $114.69 and its 200 day simple moving average is $104.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a market capitalization of $26.83 billion, a PE ratio of -53.30 and a beta of 0.18. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same quarter in the previous year, the business earned $0.73 earnings per share. The business’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, research analysts anticipate that BioNTech will post -3.71 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.